Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
D 1.04 0.97% 0.01
OVID closed up 0.97 percent on Wednesday, November 20, 2024, on 1.26 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal 0.97%
Lower Bollinger Band Walk Weakness 0.97%
Down 3 Days in a Row Weakness 0.97%
Down 4 Days in a Row Weakness 0.97%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 2% about 18 hours ago
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ovid Therapeutics Inc. Description

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Syndromes Urological Disorders Genodermatoses Sedatives Fragile X Syndrome Anticonvulsants Rare Neurological Disorders

Is OVID a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.1
52 Week Low 0.68
Average Volume 171,595
200-Day Moving Average 2.02
50-Day Moving Average 1.16
20-Day Moving Average 1.18
10-Day Moving Average 1.17
Average True Range 0.09
RSI (14) 36.31
ADX 18.57
+DI 17.30
-DI 24.36
Chandelier Exit (Long, 3 ATRs) 1.20
Chandelier Exit (Short, 3 ATRs) 1.26
Upper Bollinger Bands 1.37
Lower Bollinger Band 1.00
Percent B (%b) 0.11
BandWidth 31.08
MACD Line -0.02
MACD Signal Line 0.00
MACD Histogram -0.0282
Fundamentals Value
Market Cap 73.51 Million
Num Shares 70.7 Million
EPS -0.68
Price-to-Earnings (P/E) Ratio -1.53
Price-to-Sales 956.20
Price-to-Book 2.71
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.10
Resistance 3 (R3) 1.10 1.08 1.09
Resistance 2 (R2) 1.08 1.06 1.08 1.09
Resistance 1 (R1) 1.06 1.06 1.07 1.06 1.08
Pivot Point 1.04 1.04 1.04 1.04 1.04
Support 1 (S1) 1.02 1.02 1.03 1.02 1.00
Support 2 (S2) 1.00 1.02 1.00 0.99
Support 3 (S3) 0.98 1.00 0.99
Support 4 (S4) 0.98